Income Statement

v3.8.0.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
REVENUES    
Real property rental $ 296,623
Development services and sales of developed products 11,290
Medical related consulting services - related parties 66,286
Total Revenues 307,913 66,286
COSTS AND EXPENSES    
Real property operating expenses 210,274
Development services and sales of developed products 16,520
Medical related consulting services - related parties 99,581
Total Costs and Expenses 226,794 99,581
REAL PROPERTY OPERATING INCOME 86,349
GROSS LOSS FROM DEVELOPMENT SERVICES AND SALES OF DEVELOPED PRODUCTS (5,230)
GROSS LOSS FROM MEDICAL RELATED CONSULTING SERVICES (33,295)
OTHER OPERATING EXPENSES:    
Selling expense 8,711
Compensation and related benefits 538,814 182,927
Professional fees 571,772 207,218
Other general and administrative 285,252 60,732
Total Other Operating Expenses 1,395,838 459,588
LOSS FROM OPERATIONS (1,314,719) (492,883)
OTHER INCOME (EXPENSE)    
Interest income 408 794
Interest expense (236,986)
Foreign currency transaction loss (57,244)
Other income 328
Total Other Expense, net (236,250) (56,450)
LOSS BEFORE INCOME TAXES (1,550,969) (549,333)
INCOME TAXES
NET LOSS (1,550,969) (549,333)
LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (69,390)
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. (1,481,579) (549,333)
COMPREHENSIVE LOSS    
NET LOSS (1,550,969) (549,333)
Unrealized foreign currency translation gain (loss) 52,838 (39,771)
COMPREHENSIVE LOSS (1,498,131) (589,104)
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (69,230)
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS $ (1,428,901) $ (589,104)
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS    
Basic and diluted $ (0.02) $ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic and diluted 69,781,733 62,595,289

Source